Input Requested for Zepatier’s BC PharmaCare Review

Input Requested for Zepatier's BC PharmaCare ReviewZepatier’s BC PharmaCare Review Questionnaires (Once on the page, scroll down until you see a colourful table.)

Zepatier (elbasvir – grazoprevir) is being considered for BC PharmaCare coverage. As part of this process, BC PharmaCare has given BC patients, caregivers, and patient groups the opportunity to become a part of this drug review and share their opinions and perspectives with the decision makers.

If you are interested in grabbing this opportunity to voice your opinions, the link above will take you to the questionnaires. The link will also take you to BC PharmaCare’s Drug Information sheet and to information about BC PharmaCare’s approval process.

The questionnaires will ONLY remain open until MIDNIGHT ON Wednesday April 20, 2016.

Adding Your Voice to the BC PharmaCare Coverage Review for Zepatier

If you answer yes to any of the following questions, you can give your input:

Zepatier (elbasvir – grazoprevir)

Zepatier is a Health Canada approved, all-oral, short-course (8, 12, or 16 weeks), interferon-free treatment for hep C genotype 1, 3, or 4. The treatment can be prescribed with or without ribavirin and with or without Sovaldi. It has a high cure rate.

Links to Additional Information about Zepatier

For more information, please contact BC PharmaCare’s Your Voice or the Hepatitis C Treatment Information Project.

Take the time to voice your opinion and help advocate for a better tomorrow!